• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

NVIDIA Healthcare Launches Generative AI Microservices for Drug Discovery

by Syed Hamza Sohail 03/19/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

  • NVIDIA today launched more than two dozen new microservices that allow healthcare enterprises worldwide to take advantage of the latest advances in generative AI from anywhere and on any cloud.
  • The new suite of NVIDIA healthcare microservices includes optimized NVIDIA NIM AI models and workflows with industry-standard APIs, or application programming interfaces, to serve as building blocks for creating and deploying cloud-native applications. They offer advanced imaging, natural language and speech recognition, and digital biology generation, prediction and simulation.

Empowering Healthcare Innovation: Introducing NVIDIA NIM Healthcare Microservices

Moreover, NVIDIA’s suite of accelerated software development kits and tools, such as Parabricks, MONAI, NeMo, Riva, and Metropolis, are now accessible as NVIDIA CUDA-X microservices. These microservices, with 25 newly launched offerings, are poised to expedite healthcare workflows in drug discovery, medical imaging, and genomics analysis.

This advancement in microservices stands to catalyze transformation within healthcare organizations, particularly as generative AI opens up myriad opportunities for pharmaceutical firms, medical professionals, and healthcare facilities. These opportunities encompass screening vast arrays of drug compounds to propel medical advancements, improving the quality of patient data for early disease detection, and deploying more intelligent digital assistants.

By enabling researchers, developers, and practitioners to seamlessly integrate AI into both new and existing applications, these microservices empower them to operate across various environments—from cloud-based platforms to on-premises setups. This equips them with co-pilot capabilities, enhancing their efforts in life-saving endeavors.

“For the first time in history, we can represent the world of biology and chemistry in a computer, making computer-aided drug discovery possible,” said Kimberly Powell, vice president of healthcare at NVIDIA. “By helping healthcare companies easily build and manage AI solutions, we’re enabling them to harness the full power and potential of generative AI.”

NVIDIA NIM Healthcare Microservices for Inference presents a suite meticulously tailored to optimize inference operations across a spectrum of healthcare domains, including imaging, medical technology, drug discovery, and digital health. Within the NVIDIA AI Enterprise 5.0 software platform, NIM provides elevated capabilities in generative biology, chemistry, and molecular prediction.

These microservices incorporate specialized models such as MolMIM for generative chemistry, ESMFold for protein structure prediction, and DiffDock for comprehending drug-target interactions. Furthermore, VISTA 3D expedites the development of 3D segmentation models, while the Universal DeepVariant significantly accelerates genomic analysis, boasting a 50x speed improvement over CPU-based approaches.

Cadence, a computational software leader, integrates NVIDIA BioNeMo microservices into its Orion molecular design platform, enhancing drug discovery capabilities. Over 50 application providers, biotech firms, pharma companies, and medical imaging software makers utilize these microservices, including industry players like Amgen, Astellas, and DNA Nexus.

Generative AI is revolutionizing patient care, with companies like Hippocratic AI developing task-specific Generative AI Healthcare Agents powered by safety-focused LLM. Connected to NVIDIA’s Avatar Cloud Engine (ACE) microservices and utilizing NIM for low-latency inferencing, these agents conduct various patient interactions, from appointment scheduling to post-discharge follow-ups.

Abridge is pioneering an AI-powered clinical conversation platform that streamlines note drafting for clinicians, saving up to three hours daily. This system employs various AI technologies for real-time conversion of clinical conversations into structured, high-quality documentation, facilitating efficient patient care.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Drug Discovery, Generative AI

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |